| 10/08/26 | 07:00:08 | 10 Aug 2026 | | Bioanalytical CRO partner for Kapiglucagon | RNS |
| 22/07/26 | 07:00:03 | 22 Jul 2026 | | Thermo Fisher CDMO selected for Kapiglucagon pro | RNS |
| 25/06/26 | 13:20:57 | 25 Jun 2026 | | 2026 RESULT OF ANNUAL GENERAL MEETING | RNS |
| 25/06/26 | 07:00:07 | 25 Jun 2026 | | ImmuPharma appoints Bachem for Kapiglucagon API | RNS |
| 24/06/26 | 07:00:06 | 24 Jun 2026 | | University of Murcia research relating to P140 | RNS |
| 04/06/26 | 07:10:09 | 4 Jun 2026 | | Incanthera plc – Corporate Update & Board Changes | RNS |
| 02/06/26 | 07:00:02 | 2 Jun 2026 | | Notice of AGM & Annual Report & Accounts | RNS |
| 27/05/26 | 07:00:03 | 27 May 2026 | | Final Results | RNS |
| 05/05/26 | 07:00:18 | 5 May 2026 | | IMM initiatesIND-Enabling Program for Kapiglucagon | RNS |
| 10/04/26 | 07:00:04 | 10 Apr 2026 | | Holding(s) in Company | RNS |
| 09/04/26 | 07:00:08 | 9 Apr 2026 | | Chairman’s Open Letter to Shareholders | RNS |
| 07/04/26 | 11:45:21 | 7 Apr 2026 | | Result of General Meeting and TVR | RNS |
| 27/03/26 | 07:00:05 | 27 Mar 2026 | | P140 Program Update | RNS |
| 23/03/26 | 07:00:09 | 23 Mar 2026 | | Result of WRAP Retail Offer and TVR | RNS |
| 19/03/26 | 09:00:00 | 19 Mar 2026 | | Publication of Circular | RNS |
| 18/03/26 | 07:00:12 | 18 Mar 2026 | | ‘Investor Meet Company’ presentation on 20 March | RNS |
| 17/03/26 | 07:01:01 | 17 Mar 2026 | | WRAP Retail Offer for up to £1.5 million | RNS |
| 17/03/26 | 07:00:10 | 17 Mar 2026 | | P140 Update; Fundraise, Related Party Transaction | RNS |
| 06/01/26 | 16:11:35 | 6 Jan 2026 | | Holding(s) in Company | RNS |
| 06/01/26 | 07:00:08 | 6 Jan 2026 | | Attending JPMorgan Conference & Biotech Showcase | RNS |
| 24/11/25 | 07:00:11 | 24 Nov 2025 | | Corporate Update | RNS |
| 04/11/25 | 07:00:12 | 4 Nov 2025 | | Holding(s) in Company | RNS |
| 27/10/25 | 07:00:13 | 27 Oct 2025 | | IMMUPHARMA ATTENDING BIO-EUROPE | RNS |
| 23/10/25 | 07:00:01 | 23 Oct 2025 | | Launch of Website; Corporate Update | RNS |
| 13/10/25 | 07:00:12 | 13 Oct 2025 | | Appointment of Independent Non-Executive Director | RNS |
| 06/10/25 | 15:22:46 | 6 Oct 2025 | | Holding(s) in Company | RNS |
| 17/09/25 | 07:00:02 | 17 Sept 2025 | | Exercise of Warrants | RNS |
| 11/09/25 | 07:00:08 | 11 Sept 2025 | | Exercise of Warrants | RNS |
| 01/09/25 | 14:12:05 | 1 Sept 2025 | | Appointments of CSO and Head of R&D | RNS |
| 01/09/25 | 13:20:32 | 1 Sept 2025 | | ImmuPharma Files New Patent Application for P140: | RNS |
| 20/08/25 | 13:36:49 | 20 Aug 2025 | | Holding(s) in Company | RNS |
| 06/08/25 | 07:00:09 | 6 Aug 2025 | | Interim Results | RNS |
| 12/06/25 | 12:51:00 | 12 Jun 2025 | | Result of AGM | RNS |
| 27/05/25 | 15:13:18 | 27 May 2025 | | Holding(s) in Company | RNS |
| 20/05/25 | 07:00:12 | 20 May 2025 | | Notice of AGM | RNS |
| 19/05/25 | 07:00:06 | 19 May 2025 | | Final Results | RNS |
| 01/04/25 | 07:00:12 | 1 Apr 2025 | | Warrant Extension, Debt Conversion & Equity Issue | RNS |
| 01/04/25 | 07:00:10 | 1 Apr 2025 | | Extension of Warrants in Incanthera to 30 Sep 2025 | RNS |
| 14/03/25 | 07:00:13 | 14 Mar 2025 | | IMM attending Bio-Europe Spring 17-19 March,Milan | RNS |
| 13/03/25 | 07:00:12 | 13 Mar 2025 | | ImmuPharma proves unique Mechanism of Action-P140 | RNS |
| 21/02/25 | 11:36:55 | 21 Feb 2025 | | Holding(s) in Company | RNS |
| 13/02/25 | 07:00:07 | 13 Feb 2025 | | £2.91m fundraising; related party transactions | RNS |
| 28/01/25 | 12:57:44 | 28 Jan 2025 | | Response to Share Price Movement | RNS |
| 09/01/25 | 07:00:04 | 9 Jan 2025 | | Breakthrough Findings into Autoimmune Diseases | RNS |
| 08/01/25 | 07:00:06 | 8 Jan 2025 | | IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE | RNS |
| 23/12/24 | 07:00:06 | 23 Dec 2024 | | Change of Auditor | RNS |
| 10/12/24 | 14:36:12 | 10 Dec 2024 | | Holding(s) in Company | RNS |
| 04/12/24 | 07:00:07 | 4 Dec 2024 | | Appointment of Company Secretary | RNS |
| 09/09/24 | 07:01:00 | 9 Sept 2024 | | Extension of Warrants in Incanthera to 31 Mar 2025 | RNS |
| 09/09/24 | 07:00:08 | 9 Sept 2024 | | Half-year Report | RNS |
